肝硬化肌肉减少症的发病机制及诊治现状

刘嘉; 黄华

doi:10.3969/j.issn.1001-5256.2020.04.041

肝硬化肌肉减少症的发病机制及诊治现状

DOI: 10.3969/j.issn.1001-5256.2020.04.041

刘嘉,
黄华

昆明医科大学第二附属医院消化内科

基金项目:

云南省应用基础研究(2015FB059)；

详细信息

中图分类号: R575.2
计量
- 文章访问数: 1068
- HTML全文浏览量: 54
- PDF下载量: 266
- 被引次数: 0
出版历程
- 出版日期: 2020-04-20

Pathogenesis of sarcopenia in liver cirrhosis and current status of its diagnosis and treatment

Liu Jia,
Huang Hua

Department of Gastroenterology, The Second Affiliated Hospital of Kunming Medical University

Research funding:

摘要

摘要: 肌肉减少症是肝硬化营养不良的重要表现形式,已成为肝硬化患者不可忽视的并发症,与患者的生活质量、住院时间、并发症发生率及死亡率密切相关,且对肝移植预后有重要影响,因此,早期诊断及干预治疗对改善肝硬化患者预后极为重要。但目前国内外对于肌肉减少症的诊断标准还未达成共识。近年来随着对肌肉分子调控机制、肌肉生长相关激素、高氨血症介导的信号通路及肠道菌群作用的深入研究,肌肉减少症发生机制被逐渐认识。适当的营养干预、合理运动、降氨治疗、补充激素、分子靶向治疗等可能改善肝硬化患者肌肉质量,将是未来研究的重点。综述了近年来肝硬化肌肉减少症的相关研究,对其流行病学特点、发生机制、诊断及治疗进行简要阐述。
- 肝硬化 /
- 肌肉衰减症 /
- 诊断 /
- 治疗学
Abstract: Sarcopenia is an important manifestation of malnutrition in liver cirrhosis and has become a non-negligible complication of patients with liver cirrhosis. It is closely associated with patients' quality of life,length of hospital stay,incidence rate of complications,and mortality rate and has great impact on the prognosis of liver transplantation. Therefore,early diagnosis and intervention are of great importance in improving the prognosis of patients with liver cirrhosis. However,no consensus has been reached on the diagnostic criteria for sarcopenia in China and foreign countries. In recent years,in-depth studies of muscle molecular regulation mechanism,muscle growth-related hormones,hyperammonemia-mediated signaling pathways,and intestinal flora have gradually revealed the pathogenesis of sarcopenia.Proper nutrition intervention,reasonable exercise,ammonia reduction therapy,hormone supplementation,and molecular targeted therapy may improve muscle mass in patients with liver cirrhosis,which are important hotspots for future research. This article summarizes the recent research on sarcopenia in liver cirrhosis and elaborates on its epidemiological features,pathogenesis,diagnosis,and treatment.
- liver cirrhosis /
- sarcopenia /
- diagnosis /
- therapeutics

HTML全文

参考文献(49)

[1] FIELDING RA,VELLAS B,EVANS WJ,et al. Sarcopenia:An undiagnosed condition in older adults. Current consensus definition:Prevalence,etiology,and consequences. International working group on sarcopenia[J]. J Am Med Dir Assoc,2011,12(4):249-256.

[2] HANAI T,SHIRAKI M,OHNISHI S,et al. Rapid skeletal muscle wasting predicts worse survival in patients with liver cirrhosis[J]. Hepatol Res,2016,46(8):743-751.

[3] KIM G,KANG SH,KIM MY,et al. Prognostic value of sarcopenia in patients with liver cirrhosis:A systematic review and meta-analysis[J]. PLo S One,2017,12(10):e0186990.

[4] PONZIANI FR,GASBARRINI A. Sarcopenia in patients with advanced liver disease[J]. Curr Protein Pept Sci,2018,19(7):681-691.

[5] SINCLAIR M,GOW PJ,GROSSMANN M,et al. Review article:Sarcopenia in cirrhosis-aetiology,implications and potential therapeutic interventions[J]. Aliment Pharmacol Ther,2016,43(7):765-777.

[6] LATTANZI B,GIOIA S,di COLA S,et al. Prevalence and impact of sarcopenia in non-cirrhotic portal hypertension[J].Liver Int,2019,39(10):1937-1942.

[7] CAREY EJ,LAI JC,WANG CW,et al. A multicenter study to define sarcopenia in patients with end-stage liver disease[J]. Liver Transpl,2017,23(5):625-633.

[8] TANDON P,NEY M,IRWIN I,et al. Severe muscle depletion in patients on the liver transplant wait list:Its prevalence and independent prognostic value[J]. Liver Transpl,2012,18(10):1209-1216.

[9] HIRAOKA A,MICHITAKA K,UEKI H,et al. Sarcopenia and two types of presarcopenia in Japanese patients with chronic liver disease[J]. Eur J Gastroenterol Hepatol,2016,28(8):940-947.

[10] NARDELLI S,LATTANZI B,MERLI M,et al. Muscle alterations are associated with minimal and overt hepatic encephalopathy in patients with liver cirrhosis[J]. Hepatology,2019,70(5):1704-1713.

[11] KANG SH,JEONG WK,BAIK SK,et al. Impact of sarcopenia on prognostic value of cirrhosis:Going beyond the hepatic venous pressure gradient and MELD score[J]. J Cachexia Sarcopenia Muscle,2018,9(5):860-870.

[12] MONTANO-LOZA AJ,DUARTE-ROJO A,MEZA-JUNCO J,et al. Inclusion of sarcopenia within MELD(MELD-sarcopenia)and the prediction of mortality in patients with cirrhosis[J]. Clin Transl Gastroenterol,2015,6:e102.

[13] JEONG JY,LIM S,SOHN JH,et al. Presence of sarcopenia and its rate of change are independently associated with long-term mortality in patients with liver cirrhosis[J]. J Korean Med Sci,2018,33(50):e299.

[14] YU R,SHI Q,LIU L,et al. Relationship of sarcopenia with steatohepatitis and advanced liver fibrosis in non-alcoholic fatty liver disease:A meta-analysis[J]. BMC Gastroenterol,2018,18(1):51.

[15] MONTANO-LOZA AJ,MEZA-JUNCO J,BARACOS VE,et al. Severe muscle depletion predicts postoperative length of stay but is not associated with survival after liver transplantation[J]. Liver Transpl,2014,20(6):640-648.

[16] JOHNSON TM,OVERGARD EB,COHEN AE,et al. Nutrition assessment and management in advanced liver disease[J].Nutr Clin Pract,2013,28(1):15-29.

[17] MORRISON WL,BOUCHIER IA,GIBSON JN,et al. Skeletal muscle and whole-body protein turnover in cirrhosis[J]. Clin Sci(Lond),1990,78(6):613-619.

[18] WANG YY,LIN SY,CHUANG YH,et al. Protein nitration is associated with increased proteolysis in skeletal muscle of bile duct ligation-induced cirrhotic rats[J]. Metabolism,2010,59(4):468-472.

[19] DOMINGUES-FARIA C,CHANET A,SALLES J,et al. Vitamin D deficiency down-regulates Notch pathway contributing to skeletal muscle atrophy in old wistar rats[J]. Nutr Metab(Lond),2014,11(1):47.

[20] LATRES E,AMINI AR,AMINI AA,et al. Insulin-like growth factor-1(IGF-1)inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin(PI3K/Akt/m TOR)pathway[J]. J Biol Chem,2005,280(4):2737-2744.

[21] KHOSHNOOD A,NASIRI TM,FARAVASH MJ,et al. A survey of correlation between insulin-like growth factor-I(igf-I)levels and severity of liver cirrhosis[J]. Hepat Mon,2013,13(2):e6181.

[22] LIU W,THOMAS SG,ASA SL,et al. Myostatin is a skeletal muscle target of growth hormone anabolic action[J]. J Clin Endocrinol Metab,2003,88(11):5490-5496.

[23] QIU J,THAPALIYA S,RUNKANA A,et al. Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-kappaB-mediated mechanism[J]. Proc Natl Acad Sci USA,2013,110(45):18162-18167.

[24] MORINE KJ,BISH LT,PENDRAK K,et al. Systemic myostatin inhibition via liver-targeted gene transfer in normal and dystrophic mice[J]. PLo S One,2010,5(2):e9176.

[25] CHEN Y,ZAJAC JD,MACLEAN HE. Androgen regulation of satellite cell function[J]. J Endocrinol,2005,186(1):21-31.

[26] ESTRADA M,ESPINOSA A,MLLER M,et al. Testosterone stimulates intracellular calcium release and mitogen-activated protein kinases via a G protein-coupled receptor in skeletal muscle cells[J]. Endocrinology,2003,144(8):3586-3597.

[27] IBEBUNJO C,EASH JK,LI C,et al. Voluntary running,skeletal muscle gene expression,and signaling inversely regulated by orchidectomy and testosterone replacement[J]. Am J Physiol Endocrinol Metab,2011,300(2):e327-e340.

[28] SINCLAIR M,GROSSMANN M,HOERMANN R,et al. Testosterone therapy increases muscle mass in men with cirrhosis and low testosterone:A randomised controlled trial[J]. J Hepatol,2016,65(5):906-913.

[29] TSIEN C,DAVULURI G,SINGH D,et al. Metabolic and molecular responses to leucine-enriched branched chain amino acid supplementation in the skeletal muscle of alcoholic cirrhosis[J]. Hepatology,2015,61(6):2018-2029.

[30] LIN R,LIU W,PIAO M,et al. A review of the relationship between the gut microbiota and amino acid metabolism[J]. Amino Acids,2017,49(12):2083-2090.

[31] MANGNER N,LINKE A,OBERBACH A,et al. Exercise training prevents TNF-alpha induced loss of force in the diaphragm of mice[J]. PLo S One,2013,8(1):e52274.

[32] KO F,ABADIR P,MARX R,et al. Impaired mitochondrial degradation by autophagy in the skeletal muscle of the aged female interleukin 10 null mouse[J]. Exp Gerontol,2016,73:23-27.

[33] TICINESI A,LAURETANI F,TANA C,et al. Exercise and immune system as modulators of intestinal microbiome:Implications for the gut-muscle axis hypothesis[J]. Exerc Immunol Rev,2019,25:84-95.

[34] YAN J,HERZOG JW,TSANG K,et al. Gut microbiota induce IGF-1 and promote bone formation and growth[J]. Proc Natl Acad Sci U S A,2016,113(47):e7554-e7563.

[35] BEYER I,METS T,BAUTMANS I. Chronic low-grade inflammation and age-related sarcopenia[J]. Curr Opin Clin Nutr Metab Care,2012,15(1):12-22.

[36] BONET-PONCE L,SAEZ-ATIENZAR S,DA CASA C,et al.On the mechanism underlying ethanol-induced mitochondrial dynamic disruption and autophagy response[J]. Biochim Biophys Acta,2015,1852(7):1400-1409.

[37] CRUZ-JENTOFT AJ,BAEYENS JP,BAUER JM,et al. Sarcopenia:European consensus on definition and diagnosis:Report of the European Working Group on Sarcopenia in older people[J]. Age Ageing,2010,39(4):412-423.

[38] Chinese Society of Hepatology,Chinese Society of Gastroenterology,Chinese Medical Association. Clinical guidelines on nutrition in end-stage liver disease[J]. J Clin Hepatol,2019,35(6):1222-1230.(in Chinese)中华医学会肝病学分会，中华医学会消化病学分会．终末期肝病临床营养指南[J]．临床肝胆病杂志，2019,35(6):1222-1230.

[39] CHEN LK,LIU LK,WOO J,et al. Sarcopenia in Asia:Consensus report of the Asian Working Group for Sarcopenia[J].J Am Med Dir Assoc,2014,15(2):95-101.

[40] TSIEN C,GARBER A,NARAYANAN A,et al. Post-liver transplantation sarcopenia in cirrhosis:A prospective evaluation[J]. J Gastroenterol Hepatol,2014,29(6):1250-1257.

[41] KITAJIMA Y,TAKAHASHI H,AKIYAMA T,et al. Supplementation with branched-chain amino acids ameliorates hypoalbuminemia,prevents sarcopenia,and reduces fat accumulation in the skeletal muscles of patients with liver cirrhosis[J]. J Gastroenterol,2018,53(3):427-437.

[42] European Association for the Study of the Liver. EASL clinical practice guidelines on nutrition in chronic liver disease[J]. J Hepatol,2019,70(1):172-193.

[43] TSIEN CD,MCCULLOUGH AJ,DASARATHY S. Late evening snack:Exploiting a period of anabolic opportunity in cirrhosis[J]. J Gastroenterol Hepatol,2012,27(3):430-441.

[44] OHARA M,OGAWA K,SUDA G,et al. L-Carnitine suppresses loss of skeletal muscle mass in patients with liver cirrhosis[J]. Hepatol Commun,2018,2(8):906-918.

[45] LOCKLEAR CT,GOLABI P,GERBER L,et al. Exercise as an intervention for patients with end-stage liver disease:Systematic review[J]. Medicine(Baltimore), 2018, 97(42):e12774.

[46] ASCENZI F,BARBERI L,DOBROWOLNY G,et al. Effects of IGF-1 isoforms on muscle growth and sarcopenia[J]. Aging Cell,2019,18(3):e12954.

[47] KUMAR A,DAVULURI G,SILVA R,et al. Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis[J]. Hepatology,2017,65(6):2045-2058.

[48] HAN HQ,ZHOU X,MITCH WE,et al. Myostatin/activin pathway antagonism:Molecular basis and therapeutic potential[J]. Int J Biochem Cell Biol,2013,45(10):2333-2347.

[49] BERGERSON JT,LEE JG,FURLAN A,et al. Liver transplantation arrests and reverses muscle wasting[J]. Clin Transplant,2015,29(3):216-221.

施引文献

资源附件(0)

访问统计